Table 1 Patient characteristics
From: Hyperprogression after immunotherapy in patients with malignant tumors of digestive system
All patients (n = 25) | TGKR<2 (n = 20) | TGKR≥2 (n = 5) | P value | |
|---|---|---|---|---|
Gender | ||||
Male | 17 (68%) | 14 (70%) | 3 (60%) | 1.000 |
Female | 8 (32%) | 6 (30%) | 2 (40%) | |
Age | 54 (22–77) | 52 (22–77) | 63 (31–65) | 0.587 |
EGOG | ||||
0 | 14 (56%) | 10 (50%) | 4 (80%) | 0.341 |
1 | 11 (44%) | 10 (50%) | 1 (20%) | |
Location | ||||
stomach | 8 (32%) | 6 (30%) | 2 (40%) | 1.000 |
esophagus | 7 (28%) | 6 (30%) | 1 (20%) | |
colorectal | 7 (28%) | 5 (25%) | 2 (40%) | |
liver | 1 (4%) | 1 (5%) | 0 | |
ancreas | 1 (4%) | 1 (5%) | 0 | |
ampulla | 1 (4%) | 1 (5%) | 0 | |
Histology | ||||
adenocarcinoma | 14 (56%) | 12 (60%) | 2 (40%) | 0.032 |
squamous carcinoma | 6 (24%) | 6 (30%) | 0 | |
neuroendocrine carcinoma | 4 (16%) | 1 (5%) | 3 (60%) | |
hepatocellular carcinoma | 1 (4%) | 1 (5%) | 0 | |
Metastatic site | ||||
≤2 | 16 (64%) | 13 (65%) | 3 (60%) | 0.749 |
>2 | 9 (36%) | 7 (35%) | 2 (40%) | |
Type of immunotherapy | ||||
PD-1 inhibitor | 6 (24%) | 6 (30%) | 0 | 0.447 |
PD-L1 inhibitor | 16 (64%) | 12 (60%) | 4 (80%) | |
PD-L1 + CTLA-4 inhibitor | 3 (12%) | 2 (10%) | 1 (20%) | |
MMR | ||||
pMMR | 6 (40%) | 4 (33%) | 2 (66.7%) | 0.525 |
dMMR | 9 (60%) | 8 (67%) | 1 (33.3%) | |
PD-L1 | ||||
positive | 6 (42%) | 5 (46%) | 1 (50%) | 1.000 |
negative | 7 (54%) | 6 (55%) | 1 (50%) | |